ALMS
HEALTHCAREAlumis Inc
Live · NASDAQ · May 9, Close
What's Moving ALMS Today?
No stock-specific AI insight has been generated for ALMS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$25.50
Fundamentals
Trading
ALMS News
21 articles- Personalis (PSNL) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial ResultsYahoo Finance·Apr 6, 2026
- Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA PlansYahoo Finance·Apr 4, 2026
- Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For EnvudeucitinibYahoo Finance·Apr 4, 2026
- Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer SaysYahoo Finance·Mar 30, 2026
- Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus ReadoutMarketbeat·Mar 30, 2026
- Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisGlobeNewswire Inc.·Mar 28, 2026
- Alumis Reports Year End 2025 Financial Results and Highlights Recent AchievementsYahoo Finance·Mar 19, 2026
- Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual MeetingYahoo Finance·Mar 18, 2026
- Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price RunYahoo Finance·Mar 10, 2026
- Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout AheadMarketbeat·Mar 10, 2026
- Alumis to Present at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Mar 2, 2026
- Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare ConferenceMarketbeat·Feb 27, 2026
- Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim SummitMarketbeat·Feb 12, 2026
- Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price MomentumYahoo Finance·Feb 7, 2026
- Alumis to Participate in Upcoming February Investor ConferencesYahoo Finance·Feb 5, 2026
- Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.Motley Fool·Feb 3, 2026
- Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis TrialsYahoo Finance·Jan 30, 2026
- Huge Insider Buying Now at This Insurance Giant and 2 Biotechs247 Wall St·Jan 19, 2026
- Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity RaiseYahoo Finance·Jan 19, 2026
All 21 articles loaded
Price Data
52-Week Range
$25.50
Fundamentals
Trading
About Alumis Inc
Alumis Inc. (ALMS) is an innovative leader in the development and commercialization of high-performance aluminum products, serving critical sectors such as automotive, aerospace, and construction. The company harnesses proprietary technologies to advance material science while adhering to sustainable manufacturing practices, ensuring minimal environmental impact. Focused on research and development, Alumis is strategically positioned to capitalize on emerging market opportunities and expand its diverse product portfolio. With a commitment to operational excellence and stakeholder value, Alumis aims to sustain long-term growth through continuous innovation.